Opko Health
OPK
1.36
-0.04
-2.52%
Opko Health
US · OPK
#3224 by market cap
1.36
-0.04
-2.52%
Live - 5344 symbols - heartbeat 220s ago
· 2026-10-08 09:57
Pre-market
1.37
-1.44%
After-hours
1.39
-0.02%
Overnight
1.40
+0.72%
- Market cap
- 1.01B
- P/E (TTM)i
- -19.36
- P/Bi
- 0.85
- EPSi
- -0.30
- Div yieldi
- 0.00%
- 52W posi
- 49%
Reader sentiment
Are you bullish or bearish on OPK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -0.54, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -14.90% YoY
Margins
- Gross margin
- 33.93%
- Operating margin
- -36.08%
- Net margin
- -37.19%
Key ratios & quality
- Enterprise valuei
- 998.77M
- Altman Z-Scorei
- -0.54
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 990.27M | 901.94M | 1.44B | 1.77B | 1.00B | 863.50M | 713.14M | 606.88M |
| Gross profit | 385.63M | 329.45M | 541.01M | 581.52M | 288.22M | 318.13M | 218.51M | 205.94M |
| Selling & admin expenses | 358.35M | 343.31M | 355.57M | 468.86M | 372.67M | 300.56M | 304.22M | 223.00M |
| Research & development | 125.59M | 117.87M | 75.32M | 76.85M | 73.89M | 89.59M | 105.21M | 124.03M |
| Operating profit | -166.24M | -196.51M | 53.73M | -14.46M | -246.12M | -158.06M | -273.56M | -218.99M |
| Pretax profit | -177.27M | -304.97M | 48.68M | -14.03M | -391.52M | -184.32M | -10.36M | -241.36M |
| Tax | -38.73M | 7.06M | 17.62M | 15.49M | -63.50M | 4.44M | 42.84M | -15.71M |
| Net profit | -153.04M | -314.93M | 30.59M | -30.14M | -328.41M | -188.86M | -53.22M | -225.68M |
| Basic EPS | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.27 | -0.53 | 0.05 | -0.05 | -0.46 | -0.25 | -0.08 | -0.30 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 149.95M | 156.81M | 151.67M | 148.45M | 124.20M | 163.58M |
| Gross profit | 42.62M | 49.40M | 49.89M | 64.03M | 45.76M | 80.02M |
| Selling & admin expenses | 59.09M | 59.60M | 53.80M | 50.52M | 48.61M | 52.92M |
| Research & development | 30.84M | 30.34M | 30.08M | 32.77M | 29.20M | 33.17M |
| Operating profit | -67.17M | -59.98M | -53.52M | -38.32M | -51.02M | -25.04M |
| Pretax profit | -73.37M | -162.52M | 41.43M | -46.90M | -60.96M | -13.40M |
| Tax | -5.77M | -14.08M | 19.80M | -15.66M | -6.11M | -4.98M |
| Net profit | -67.61M | -148.44M | 21.63M | -31.26M | -54.85M | -8.42M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.10 | -0.19 | 0.03 | -0.04 | -0.07 | -0.01 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 317.73M | 324.05M | 523.18M | 823.01M | 394.53M | 309.48M | 662.09M | 581.88M |
| Cash & ST investments | 96.47M | 85.45M | 72.21M | 134.71M | 153.19M | 95.88M | 431.94M | 369.07M |
| Inventory | 42.30M | 53.43M | 132.34M | 86.50M | 74.06M | 65.70M | 56.80M | 65.82M |
| Total assets | 2.45B | 2.31B | 2.47B | 2.40B | 2.17B | 2.01B | 2.20B | 1.93B |
| Total current liabilities | 288.32M | 249.12M | 375.48M | 330.01M | 213.48M | 200.05M | 193.10M | 146.68M |
| Short-term debt | 40.69M | 24.40M | 36.18M | 28.58M | 51.03M | 43.12M | 29.35M | 22.86M |
| Long-term debt | 167.15M | 259.86M | 225.83M | 190.16M | 219.47M | 222.03M | 422.18M | 333.72M |
| Total liabilities | 659,781,000.00 | 694,513,000.00 | 801,512,000.00 | 714,589,000.00 | 605,611,000.00 | 622,479,000.00 | 834,764,000.00 | 663,985,000.00 |
| Total equity | 1.79B | 1.61B | 1.67B | 1.69B | 1.56B | 1.39B | 1.37B | 1.27B |
| Retained earnings | -1.20B | -1.51B | -1.48B | -1.51B | -1.82B | -2.01B | -2.07B | -2.29B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 737.60M | 583.33M | 627.13M | 581.88M | 535.36M | 500.24M |
| Cash & ST investments | 436.00M | 271.72M | 415.20M | 369.07M | 341.88M | 300.76M |
| Inventory | 64.00M | 66.35M | 64.95M | 65.82M | 64.40M | 61.85M |
| Total assets | 2.13B | 1.97B | 2.00B | 1.93B | 1.86B | 1.83B |
| Total current liabilities | 295.86M | 171.18M | 169.32M | 146.68M | 148.38M | 149.37M |
| Short-term debt | 124.89M | 25.51M | 24.35M | 22.86M | 22.26M | 22.96M |
| Long-term debt | 325.85M | 329.25M | 331.43M | 333.72M | 336.03M | 338.49M |
| Total liabilities | 816,664,000.00 | 676,085,000.00 | 690,018,000.00 | 663,985,000.00 | 652,186,000.00 | 645,287,000.00 |
| Total equity | 1.31B | 1.30B | 1.31B | 1.27B | 1.20B | 1.18B |
| Retained earnings | -2.13B | -2.28B | -2.26B | -2.29B | -2.35B | -2.35B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -109.14M | -172.52M | 39.48M | 38.34M | -95.19M | -28.20M | -183.49M | -178.54M |
| Depreciation & amortization | 97.34M | 93.81M | 85.36M | 78.72M | 108.66M | 105.30M | 98.18M | 91.63M |
| Free cash flow | -137.00M | -185.26M | 5.79M | 6.18M | -119.77M | -44.47M | -208.50M | -190.82M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 92.50M | 76.06M | -- | -- | 0 | 0 | -90.22M | -47.04M |
| Ending cash balance | 96.47M | 85.45M | 72.21M | 134.71M | 153.19M | 95.88M | 445.62M | 382.74M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -34.55M | -83.42M | -34.65M | -25.92M | -19.31M | -43.50M |
| Depreciation & amortization | 23.49M | 23.03M | 22.74M | 22.37M | 22.20M | 22.41M |
| Free cash flow | -37.75M | -86.70M | -37.78M | -28.59M | -21.14M | -46.50M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -18.26M | -15.28M | -13.51M | -4.77M | -13.02M |
| Ending cash balance | 449.68M | 285.40M | 428.87M | 382.74M | 355.57M | 314.43M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -8.32 | -18.49 | 1.86 | -1.80 | -20.23 | -12.80 | -3.86 | -17.14 |
| ROA %i | -6.08 | -13.23 | 1.28 | -1.24 | -14.38 | -9.04 | -2.53 | -10.92 |
| ROIC %i | -7.14 | -15.27 | 2.28 | -0.84 | -16.81 | -10.12 | -1.25 | -7.82 |
| 5-year avg ROE %i | -9.68 | -9.39 | -8.59 | -8.47 | -9.42 | -10.29 | -7.37 | -11.17 |
| EBIT margin %i | -16.70 | -31.43 | 4.92 | 0.27 | -37.79 | -19.78 | 5.20 | -21.90 |
| FCF / sales %i | -- | -- | 0.40 | 0.35 | -- | -- | -- | -- |
| Current ratioi | 1.10 | 1.30 | 1.39 | 2.49 | 1.85 | 1.55 | 3.43 | 3.97 |
| Quick ratioi | 0.90 | 0.98 | 1.00 | 1.21 | 1.41 | 1.13 | 3.02 | 3.38 |
| Debt / assetsi | 8.71 | 13.68 | 11.91 | 10.62 | 14.10 | 16.23 | 22.93 | 20.54 |
| LT debt / equityi | 9.65 | 18.06 | 15.46 | 13.42 | 16.30 | 20.40 | 34.79 | 29.49 |
| Interest coveragei | -13.91 | -13.17 | 3.22 | 0.26 | -31.48 | -12.65 | 0.78 | -1.23 |
| Revenue CAGR (3Y) %i | 26.28 | -6.89 | 14.11 | 21.47 | 3.64 | -15.58 | -26.21 | -15.45 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -3.04 | -13.16 | -13.32 | -17.14 | -16.92 | -5.88 |
| ROA %i | -1.90 | -8.96 | -8.49 | -10.92 | -10.69 | -3.83 |
| ROIC %i | -0.29 | -5.74 | -5.78 | -7.82 | -7.54 | -2.67 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 7.93 | -5.29 | -7.49 | -21.90 | -21.51 | -5.93 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.49 | 3.41 | 3.70 | 3.97 | 3.61 | 3.35 |
| Quick ratioi | 1.91 | 2.37 | 3.19 | 3.38 | 3.03 | 2.78 |
| Debt / assetsi | 23.16 | 20.06 | 19.82 | 20.54 | 21.38 | 21.76 |
| LT debt / equityi | 28.06 | 28.55 | 28.42 | 29.49 | 31.10 | 31.68 |
| Interest coveragei | 0.99 | -0.30 | -0.43 | -1.23 | -1.20 | -0.77 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Pharmaceutical is the largest reported line at 54.43% of revenue, across 2 reported segments.
- Diagnostics follows at 45.57%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Pharmaceutical54.43%
Diagnostics45.57%
Quote time 2026-10-08 09:57:34 · For reference only, not investment advice and not tailored to your situation.